# Ascentawits Pharmaceuticals

Source: https://onco.cc/companies/ascentawits-pharmaceuticals/  
OnCo record `ascentawits-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ascentawits Pharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of AST-3424 and AST-001 in hepatocellular carcinoma and pancreatic ductal adenocarcinoma.

## Summary

Ascentawits Pharmaceuticals, based in Shenzhen, China, is a biotechnology company. Ascentawits Pharmaceuticals (Shenzhen Ascenta Wits Pharmaceutical Technology Co., Ltd.) develops small molecule-drug conjugates as targeted cancer therapeutics. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AST-3424 and AST-001 in hepatocellular carcinoma and pancreatic ductal adenocarcinoma. The largest, NCT06245330 (A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumours), plans to enrol 180 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Ascentawits Pharmaceuticals, Ltd
- Tags: ctgov-sponsor
- HQ: Shenzhen
- Type: biotech
- Website: https://www.ascentawits.com

## Sources

- Official website: https://www.ascentawits.com
- ClinicalTrials.gov: trials led by Ascentawits Pharmaceuticals: https://clinicaltrials.gov/search?lead=Ascentawits%20Pharmaceuticals%2C%20Ltd

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- trials: [A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct06245330/), [A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct06239155/)

---
JSON: https://onco.cc/api/v1/entities/ascentawits-pharmaceuticals.json